RDHL Stock Recent News
RDHL LATEST HEADLINES
Redhill Biopharma (NASDAQ: RDHL ) stock is sliding lower on Thursday but only after the company's shares come off of a recent rally. Shares of RDHL stock saw major gains earlier in the week.
RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori.
Amid a slow start to the new week, specialty drug developer RedHill Biopharma (NASDAQ: RDHL ) dramatically enlivened the mood, skyrocketing over 180% during the early afternoon session. Catapulting sentiment was regulatory approval for Talicia, a therapeutic designed to target helicobacter pylori (H.
RedHill Biopharma Ltd.'s stock RDHL, +1.65% soared 10% premarket after the company said it has received a further $1.7 million in U.S. government funding for its partner, Apogee, to develop a treatment for gastrointestinal acute radiation syndrome.
Understand how market trends impact penny stocks The post The Impact of Market Trends on Penny Stocks Performance appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Friday after getting positive patent news from the U.S. Patent and Trademark Office (USPTO). The USPTO issued a Notice of Allowance that grants the company a patent for RHB-204's treatment methods.
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Wednesday after the company received a patent for one of its oral antiviral treatments. That patent covers the administration of opaganib.
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease